LexBio Named a '2025 NVIDIA Honored Enterprise' for Advancing AI-Driven Drug Discovery

Jan 16, 2026 14:23 CST Updated 14:23

LexBio

AI Small Molecule New Drug Developer

Note:This article does not constitute any investment opinions or suggestions; please refer to official/company announcements for accuracy.This article only provides an introduction to drugs related to healthcare, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.

PharmaCircleMonitoring shows:

As FocusAIAs an innovative enterprise in the intersection of life sciences, LexBio always believes and practices “AIEmpowering New Drug Development, Technology Benefits Patients Worldwide” The core mission. In“2025 NVIDIA Startup Showcase (NVIDIA INCEPTION SHOWCASE 2025)”In the series of activities, the company participated in the thematic exchange in Suzhou, East China, along with industry experts, investment institutions, and industrial chain partners to discussAIAn in-depth discussion on the practical application in drug research and development was carried out, comprehensively showcasing LexBio through roadshows and startup presentations.AIInnovative achievements driving key aspects such as drug discovery and optimization of preclinical research.

WithBreakthrough Practices and Hardcore Technical Strength in AI-Empowered New Drug R&DLexBioFromStanding out among more than 460 participating companies, LexBio successfully clinched the annual "Glory Enterprise" award, sharing the pinnacle stage of the industry with nine other outstanding companies!

Awarded this timeNVIDIA's "Honored Enterprise" of the Year, is not only a recognition of LexBio's technological innovationAbilityAnd BusinessChemicalHigh recognition of potential,AlsoIs a testament to our commitment"Protecting Life and Health with Technology" is a great encouragement to our original aspiration. Behind this honor, the hard work of the team and NVIDIA cannot be overlooked. InceptionStartup Acceleration Program ProvidesofTechnologyGuidance, resource对接and global展示platform, cannot be achieved without the trust and support of industry partners.

Standing at a new starting point, LexBio will take this award as an opportunity to further deepen cooperation withNVIDIA and GlobalBiopharmaceuticalsPartnership cooperation, give full play toThe Core Value of AI Technology in the Entire Process of Drug Development: Focusing on Unmet Clinical Needs to Accelerate the R&D and Transformation of Innovative Drugs. We will continue to uphold the concept of "Innovation, Rigor, Collaboration, and Win-Win," and deeply cultivate the biopharmaceutical track.PromoteAI-Empowered InnovationResultsBenefit global patients more quickly and contribute more to the cause of human health!

FutureExpected, the journey continues. LexBio will carry this honor and responsibility in“AI + Biomedicine”On the roadPolishMoving forward, we look forward to joining hands with more like-minded partners to jointly write a new chapter in the innovative development of biopharmaceuticals!

About LexBio

LexBio is a biotechnology company centered on artificial intelligence, leveraging its proprietary AI drug discovery platform KINET.™Completely transform the way drugs are discovered. We integrate large-scale biomedical data,Advanced DepthLearning and high-performance computing provide efficient and precise comprehensive solutions for new drug development.LexBio's internal innovative drug pipeline covers disease areas such as oncology, inflammation and immunology, and CNS, and conducts flexible and diverse project collaborations with academia and industry worldwide.